CompletedPhase 1NCT02133846

Safety Study of TPI-287 to Treat CBS and PSP

Studying Classic progressive supranuclear palsy syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of California, San Francisco
Principal Investigator
Adam Boxer, MD, PhD
UCSF Memory and Aging Center
Intervention
TPI 287 2 mg/m2(drug)
Enrollment
44 enrolled
Eligibility
50-85 years · All sexes
Timeline
20142019

Study locations (2)

Collaborators

CBD Solutions · Tau Consortium

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02133846 on ClinicalTrials.gov

Other trials for Classic progressive supranuclear palsy syndrome

Additional recruiting or active studies for the same condition.

See all trials for Classic progressive supranuclear palsy syndrome

← Back to all trials